Sotagliflozin Patent Expiration
Sotagliflozin is Used for reducing the risk of cardiovascular events in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. It was first introduced by Lexicon Pharmaceuticals Inc
Sotagliflozin Patents
Given below is the list of patents protecting Sotagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inpefa | US8217156 | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use | Oct 07, 2030 | Lexicon Pharms Inc |
| Inpefa | US8476413 | Sulfanyl-tetrahydropyran-based compounds and methods of their use | May 29, 2028 | Lexicon Pharms Inc |
| Inpefa | US7781577 | Inhibitors of sodium glucose co-transporter 2 and methods of their use | May 04, 2028 | Lexicon Pharms Inc |
Sotagliflozin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sotagliflozin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Lexicon Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. | HealthPartners Institute | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity | Icahn School of Medicine at Mount Sinai | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Alessandro Doria | NA |
RECRUITING
(Mar 1, 2026)
| PHASE3 |